Congenital factor VII deficiency. A report of four new cases.
Four new cases with congenital homozygous factor VII deficiency are described. Factor VII levels were reduced to less than 1%, 3%, 8% and 10%, respectively. The incidence and severity of bleeding symptoms were well correlated with the measured factor VII activity. In the severe case of factor VII deficiency (less than 1%) a home treatment program was started because of severe recurrent hemarthroses. This entailed transfusions of 20 U/kg body weight prothrombin complex or factor VII concentrate in case of acute bleeding approximately every three weeks. These transfusions have been carried out successfully without any problems. In contradiction, two brothers with hypoproconvertinemia (factor VII 8% and 10% respectively) reached an age of more than 70 years. Despite replacement therapy postoperative bleeding followed one appendectomy, whereas no postoperative bleeding followed patients requiring Achilles tendon lengthening and an above knee amputation and only slight bleeding followed a tonsillectomy. Based on our experience we suggest that in patients with factor VII deficiency of less than 10%, when undergoing surgery, should be maintained a minimal factor VII activity of 10--15% during the first three postoperative days.
D000293:Adolescent; D000368:Aged; D005167:Factor VII / Q000627:therapeutic use; D005168:Factor VII Deficiency / Q000151:congenital* / Q000188:drug therapy; D006395:Hemarthrosis / Q000209:etiology; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D008297:Male; D011516:Prothrombin / Q000627:therapeutic use; D013514:Surgical Procedures, Operative
D005167:Factor VII; D011516:Prothrombin